“…Regarding menopausal status, 4 interventions did not report it [ 25 , 30 , 31 , 33 , 34 ], in 2 interventions all participants were postmenopausal [ 32 , 37 ] and in 6 interventions, postmenopausal participants were between 40.0% and 90.0% of the total participants [ 26 , 27 , 28 , 29 , 35 , 36 ]. Regarding hormone therapy (HT) intake by participants, in 6 interventions they were receiving tamoxifen and aromatase inhibitors [ 28 , 29 , 34 , 35 , 36 , 37 ], 1 intervention tamoxifen [ 30 , 31 ], 1 intervention aromatase inhibitors plus selective estrogen receptor modulator [ 32 ], in 1 intervention the type of HT was not specified [ 25 ] and in 3 interventions it was not specified whether they were on HT or not [ 26 , 27 , 33 ]. Among all interventions, there were two interventions where all participants were receiving HT [ 29 , 30 , 31 ].…”